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Abstract
Background: Technical advances in the collection of clinical material, such as laser capture microdissection and cell sorting,
provide the advantage of yielding more refined and homogenous populations of cells. However, these attractive
advantages are counter balanced by the significant difficultly in obtaining adequate nucleic acid yields to allow
transcriptomic analyses. Established technologies are available to carry out global transcriptomics using nanograms of input
RNA, however, many clinical samples of low cell content would be expected to yield RNA within the picogram range. To
fully exploit these clinical samples the challenge of isolating adequate RNA yield directly and generating sufficient
microarray probes for global transcriptional profiling from this low level RNA input has been addressed in the current report.
We have established an optimised RNA isolation workflow specifically designed to yield maximal RNA from minimal cell
numbers. This procedure obtained RNA yield sufficient for carrying out global transcriptional profiling from vascular
endothelial cell biopsies, clinical material not previously amenable to global transcriptomic approaches. In addition, by
assessing the performance of two linear isothermal probe generation methods at decreasing input levels of good quality
RNA we demonstrated robust detection of a class of low abundance transcripts (GPCRs) at input levels within the picogram
range, a lower level of RNA input (50 pg) than previously reported for global transcriptional profiling and report the ability
to interrogate the transcriptome from only 10 pg of input RNA. By exploiting an optimal RNA isolation workflow specifically
for samples of low cell content, and linear isothermal RNA amplification methods for low level RNA input we were able to
perform global transcriptomics on valuable and potentially informative clinically derived vascular endothelial biopsies here
for the first time. These workflows provide the ability to robustly exploit ever more common clinical samples yielding
extremely low cell numbers and RNA yields for global transcriptomics.
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Introduction
Microarray technologies permitting global gene expression
profiling have represented a major advance in genomic science.
Gene expression profiles can generate parallel quantitative and
repeated measurements of tens of thousands of transcripts
simultaneously in one sample, allowing rational comparison of
the transcriptome across a vast array of experimental conditions.
Several advances in RNA amplification techniques and micro-
array technologies have led to the wide use of global gene
expression profiling in biomedical research, adopted as standard in
both academia and industry [1,2,3]. These capabilities can
frequently provide powerful insights into biological processes
underlying disease and through translational research can
underpin generation of target gene modules for potential use in
molecular disease diagnosis and prognosis, and in patient
stratification schema and prediction of therapeutic outcome in
personalised medicine strategies [4,5].
Historically, microarray probe generation has been achieved by
in vitro transcription (IVT) with T7 RNA polymerase of double-
stranded cDNA, firstly generated by reverse-transcription of
mRNA utilising a poly(T) oligonucleotide complementary to the
39 poly(A) tail of mRNA (or internal poly(A) tracts) [6], requiring
total RNA input within the microgram range [7,8]. Advances in
sample collection techniques such as fine needle aspiration, laser
capture micro-dissection (LCM) and cell sorting now provide the
opportunity to interrogate the transcriptome of more homoge-
nous, refined cell populations. However, these types of material
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yields. Early attempts at using fine needle aspirates for microarray
based global gene expression profiling have been largely
unsuccessful due to only a small percentage (,15%) of samples
providing sufficient RNA quantities required for the probe
generation methods of the time [9]. These studies were
subsequently followed by a more targeted approach allowing
assessment of a small number of pre-defined target mRNAs [9,10].
The few studies which have reported successful profiling from fine
needle aspiration biopsies have done so using biopsies from
tumour samples which provide at least 1 mg of total RNA to use as
input for probe generation [11].
More targeted approaches to gene expression profiling, such as
real-time quantitative PCR (qPCR), have the advantage of
conceptually requiring less input material and indeed are vital in
validating gene expression profiles identified and inferred from
array-based global transcriptome datasets and as the molecular
platform in standard nucleic acid molecular diagnostics. qPCR
used along side advances in microfluidics technology has
demonstrated the possibility of gene expression analysis at the
single cell level [12,13]. However, qPCR technologies, regardless
of sensitivity, are limited to providing expression levels of
predetermined genes and as such, inherently restrict the potential
for novel discovery. Information from greater numbers of
transcripts can be generated using the technique of poly-A tailed
mRNA sequencing, however, commercially available kits for this
technique still require up to micrograms of input material. The
growing potential of sequencing to carry out transcriptomics has
been recently demonstrated by reports of this technology being
used at the single cell level [14].
In response to growing requirements to carry out global gene
expression profiling on limited sample material further advances in
RNA amplification have arisen, providing numerous technologies
claiming the ability to process RNA amounts within the nanogram
range [15,16,17,18]. Using these methods several groups have
reported global transcriptomics data from LCM and flow
cytometry collected cells by in vitro transcription-based methods
using 100 and 200 ng of input RNA, respectively, followed by
hybridisation to Affymetrix GeneChips [19,20].
Continuing technical advances in sample collection or dissection
have consequently resulted in informative interrogation of
important clinical material comprised of hundreds or thousands
of cells rather than from millions as was previously possible
[21,22]. However, some attempts at microarray experiments using
these clinical samples of reduced cell content have either pooled
individual samples to gain sufficient RNA [21] or focussed on
optimising the crucial RNA isolation step to obtain the nanograms
of RNA required for microarray analysis [22]. Microarray analysis
of 1000 endothelial cells reported the robust detection of only
hundreds of transcripts rather than the several thousands expected
from a successful and informative microarray experiment [23],
indicating successful detection of only the most abundant mRNAs
in the limited material. Given the obvious difficulties in obtaining
nanograms of RNA following direct extraction from minimal cell
numbers, or capturing the valuable inherent biological variation
following pooling of samples, there is a clear requirement for RNA
amplification methods allowing microarray probe generation from
within the picogram range of RNA to allow such investigations.
Whilst there are reports comparing RNA amplification methods
which have successfully carried out microarray gene expression
profiling from picograms of RNA [17,24,25], many have utilised
titrated dilutions of stock total RNA to within the picogram range
as the basis of support for the capabilities of the probe generation
technologies documented. However, importantly, none of these
address the issue of retrieving this level of RNA directly from
minimal cell samples such that it is applicable to microarray
workflows [17,24]. Microarray data has been obtained using RNA
isolated directly from single embryonic stem cell (ESC) colonies,
however, the authors do estimate that a single ESC colony will
yield nanograms of RNA [26]. Although possible to generate data
from single ESC colonies, in practice it was suggested that pooling
of several colonies was required to generate reliable results [26].
Successful microarray analysis on RNA isolated from minimal
cell samples has been previously reported. ESC colonies [26], 100
flow-sorted lymphocytes [27] and even individual human oocytes
and embryos, thought to yield 55 pg and 20 pg RNA, respectively
[28] have been subjected to microarray interrogation. These
reports are all based on amplification methods of two successive
rounds of amplification using 39 priming, and in some cases three
successive rounds [6]. These methods thereby potentially intro-
duce significant 39 and abundance bias, and can also resulted in
relatively low overall representation of the transcriptome [27]. The
extent of transcriptome bias introduced by the extensive 39 primed
amplification of individual oocyte or embryo templates is also
unknown, with reported reproducibility data from unamplified
versus amplified samples restricted to a subset of genes (,5000)
produced using 500 pg of RNA [28].
The ability to extract adequate material for global molecular
analyses from smaller clinical samples paves the way for less
invasive sample collection techniques within the clinic, for example
a ‘finger pick’ for blood versus a full phlebotomy procedure. Small
clinical specimens also have specific value in translational medicine
where collection is more permissive to repeated sampling,
facilitating longitudinal biomarker discovery and validation
assessments.
One clinical sample type for which the ability to carry out
transcriptional profiling (global or targeted) has previously been
significantly hampered due to lack of cell numbers and RNA yield
but could lead to significant advancements in understanding
disease mechanisms, patient stratification and disease progression
are vascular endothelial cell scraping biopsies [29]. Vascular
endothelial dysfunction plays a major role in the pathogenesis of
metabolic and cardiovascular disease [30,31,32] and further
characterisation of the vascular endothelium prior to and during
disease progression could prove useful in understanding risk
factors, disease mechanisms and identification of potential
therapeutic intervention strategies. We and others have therefore
been keen to identify molecular markers indicative and perhaps
predictive of endothelial dysfunction. To facilitate access, a
minimally invasive technique to safely collect vascular endothelial
cell biopsies from either a superficial forearm vein or the radial
artery in human subjects has been previously established [29].
Protein expression measurements by quantitative immunofluores-
cence and immunoblotting have been carried out on these
minimal endothelial cell samples [29,33], along with restricted,
targeted gene expression analyses [34]. However, due to the low
number of endothelial cells collected (mean of ,97 cells in the
current study) and the subsequent low RNA yield these types of
material have never been practically accessible for global gene
expression profiling. Considering the potential impact of obtaining
high quality and faithful global gene expression profiles using
picograms of input RNA from these vascular endothelial cell
biopsies, we first sought to establish a consistent, robust and
practical workflow to allow the application of these to global
profiling.
In order to guarantee maximum RNA yield from these minimal
cell samples, an optimised RNA isolation workflow was established
specifically designed to minimise RNA loss throughout the
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generation. For successful microarray analysis unbiased and
efficient amplification of this RNA is also required. The WT-
Ovation RNA amplification systems (NuGEN Technologies
TM,
USA) used for cDNA probe generation are commonly mentioned
in reports of microarray gene expression profiling using picograms
of RNA [17,24,27]. The Ovation systems utilise a single primer,
isothermal linear amplification (SPIA) method [17,35] to generate
single-strand cDNA microarray probes suitable for use with
Affymetrix GeneChips
TM among other platforms. Reproducibility
studies and comparison with other RNA amplification methods
have illustrated a high degree of consistence and greater
hybridisation specificity when exploiting sscDNA:DNA hybridisa-
tion compared to cRNA:DNA on microarrays [36] and reported
RNA input amounts of 250 pg using versions of this technology
[24]. More recent members of the WT-Ovation RNA amplifica-
tion system family may now provide further opportunity to exploit
minimal cell samples. The WT-Ovation FFPE RNA amplification
system V2, although principally designed to amplify sscDNA
probes from the highly degraded/fragmented and modified RNA
obtained from FFPE (formalin fixed paraffin embedded) material,
has increased SPIA amplification capacity which can conceptually
be harnessed for use with samples of good quality RNA but in low
picogram quantities. Further advances in WT-Ovation amplifica-
tion technology have come in the form of the NuGEN
Technologies
TM WT-Ovation
TM One-Direct RNA amplification
system. This system is reported to have the increased RNA
amplification potential to synthesise adequate cDNA probe from
as little as 10 pg RNA. Both of these technologies were assessed
here for performance using both varying amounts of template
RNA titrated from stocks and RNA yielded from clinically-derived
vascular endothelial cell biopsies.
In the present study we identify the optimal workflow which
allows (a) efficient RNA isolation from minimal cell numbers, (b)
efficient microarray probe generation from picograms of input
RNA which allows the continued detection of a rare class of
transcripts (widely reported to be challenging to detect by array
technology) over a range of abundances and (c) the generation of
global gene expression profiles from clinically relevant vascular
endothelial biopsies previously restricted to focussed interrogation.
Results
Optimisation of RNA isolation from minimal cell numbers
Human umbilical venous endothelial cells represent an in vitro
‘‘analogue’’ of the human vascular endothelial cell biopsies utilised
in this study [29]. To quantify the effect of various adaptations to
the RNA isolation workflow on RNA yield from minimal cell
numbers, reverse transcription followed by real-time quantitative
PCR was carried out against a calibration set processed and
prepared in parallel utilising titrated samples of HUVEC cells
(3000-200 cells) (Figure 1A).
Optimisation of the RNA isolation workflow included the
assessment of several carrier molecules (bacterial rRNA, yeast
tRNA, poly(I)(C), linear acrylamide) with combinations of
Isopropanol/Ethanol precipitation with ammonium acetate to
aid in RNA yield retention compared to commercial column-
based isolation techniques (Qiagen RNeasy Micro). Only one
carrier (poly(A) RNA) was shown to be advantageous in final yields
of RNA under the conditions assessed, but is unfortunately
incompatible with downstream array probe synthesis techniques
(data not shown). The RNeasy column-based technologies can
incorporate optional QIAshredder
TM homogenisation of the cell
lysate and an on-column DNase I treatment to eliminate genomic
DNA from subsequent RNA samples. In a series of preliminary
investigations, QIAshredder cell lysate homogenisation at low
levels of input cells, ,3000 cells was shown to be detrimental to
the resultant RNA yield compared to vigorous vortexing (data not
shown). On-column DNase I treatment also resulted in an overall
20% loss in RNA yield (data not shown). As an alternative to
Figure 1. Comparison of experimental workflows for optimised
total RNA isolation from minimal cell numbers. (A) Titrated
HUVEC samples were processed for RNA isolation through Process A or
B to establish the optimal workflow for RNA yield from minimal cell
numbers. (B) HUVECs were titrated over a range of 3000 - 200 cells per
tube and split in to 6 aliquots for cell lysis and RNA isolation. Triplicate
samples were processed using either process A or B. All samples were
then quantified by reverse transcription of the entire yielded RNA and
real-time quantitative PCR using SybrGreen probe and b-actin primers
against a standard curve of known HUVEC RNA input. Error bars =
standard deviation.
doi:10.1371/journal.pone.0017625.g001
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(Qiagen) has been demonstrated to result in genomic DNA free-
RNA, even from input template amounts of 1 mg RNA with
moderate gDNA contamination. Whilst we were able to verify no
negative effect on RNA yield of introduction of this step using this
proprietary reagent, it was also apparent that the resultant RNA
samples containing gDNA Wipeout reagent were incompatible
with downstream probe synthesis technologies, thus necessitating
removal by further purification schema.
Analysis of the resultant cDNA from both process A and
following optimisation, process B by comparison to a reference
HUVEC RNA calibration set clearly demonstrated that optimi-
sation of the RNA isolation workflow resulted in significantly
increased yields of isolated RNA (approximately 2–3 fold higher),
particularly important at the 200 cell range (Figure 1B, Table 1).
We therefore proceeded with this methodology, yielding on
average 8 pg total RNA per HUVEK cell, for downstream
microarray probe generation workflows, to achieve global
transcriptomics from input RNA in the low picogram range.
Total RNA isolation and yield from vascular endothelial
cell biopsies
Vascular endothelial cell biopsy clinical samples were collected
following written informed consent from 114 patients (cardiovas-
cular disease and healthy controls) in a study that had been
approved by the local ethics committee. Biological interpretation
of these data and accompanying clinical observations will be
reported elsewhere. All samples were processed through the
optimal RNA isolation workflow outlined here (process B).
Assessment of yielded RNA was performed by converting 10%
of the yielded RNA to cDNA in parallel with a HUVEK cell RNA
standard curve for comparative assessment using b-Actin qCPR.
The average yield across all 114 samples was 1032.66848.6 pg
(mean 6 standard deviation), with a median of 778 pg and an
absolute range of 73 pg to 5027 pg of total RNA. Of the 114
clinical biopsies, 36.8% yielded over 1 ng and 28.1% of samples
yielded less than 500 pg of RNA. With the assumption that RNA
content per cell is similar in purified endothelial cells as in
HUVEK cells, our approximations of numbers of cells yielded in
the collection procedure equates to a range of 9 to 638 cells, with a
median of 97 cells. These data illustrate the requirement for a
microarray workflow capable of operation at below 500 pg to
maximise cohort utility and successfully interrogate vascular
endothelial biopsies by microarray technology.
Efficacy of cDNA probe generation from minimal total
RNA input
The efficacies of WT-Ovation FFPE RNA amplification system
V2 and WT-Ovation One-Direct RNA amplification system were
assessed using RNA template input within the picogram range.
Both kits were assessed over a range of input levels within their
own working ranges. Previously, studies using HUVEC RNA
titrations had suggested that sscDNA probe yield and quality
would be compromised below 200 pg in the WT-Ovation FFPE
RNA amplification system (data not shown). HUVEC RNA
dilutions were split (when input overlapping across systems), used
as input template for both systems and processed in parallel
(Figure 2).
The WT-Ovation FFPE RNA amplification system V2 is
marketed for use with RNA derived from FFPE material, within a
working range of 50 ng–100 ng input. For this reason 50 ng of
high quality HUVEC RNA was used as a positive control for the
performance of the system. Quality assessment shows that the
sscDNA molecules generated from 50 ng of HUVEC RNA are of
broad distribution in length, averaging approximately 500–1000
nucleotides, suggesting efficient sscDNA synthesis (Figure 3 A). It
can be seen in Table 2 that the sscDNA yield from 50 ng of
HUVEC RNA was in excess of the 5 mg required for microarray
hybridisations. The performance of the WT-Ovation FFPE RNA
amplification system at lower RNA input levels compares
favourably in sscDNA yield (Table 2) to that obtained with
50 ng RNA input. All samples, even those at 250 pg input RNA,
yield the required 5 mg of sscDNA probe, whilst maintaining
Table 1. RNA yield from titrated HUVEC following RNA
isolation using process A or process B.
Cell input Process A RNA yield (ng) Process B RNA Yield (ng)
3000 25.26(3.5) 46.16(11.3)
1000 3.86(0.7) 11.96(1.5)
500 2.06(0.4) 5.9+(1.1)
200 0.86(0.2) 1.6+(0.3)
Cells were titrated over a range of 3000-200 cells per tube and each split equally
into 6 aliquots for subsequent cell lysis and RNA isolation by either of two
process (Process A or B). All resultant RNAs were quantified by reverse
transcription of the entire yielded RNA and quantitative real-time PCR against a
standard curve of known HUVEC total RNA input. The table shows mean total
RNA yields (numbers in parenthesis = standard deviation from three technical
replicates).
doi:10.1371/journal.pone.0017625.t001
Figure 2. Experimental workflow to assess efficiency of NuGen
probe generation technologies using low amounts of input
RNA. HUVEC total RNA was titrated to cover a range of input RNA from
50 ng–10 pg. 50 ng (n=1), 500 pg (n=2) and 250 pg (n=2) of total
RNA was used as input for the WT-Ovation FFPE system V2 while
500 pg (n=2), 250 pg (n=2), 100 pg (n=2), 50 pg (n=2) and 10 pg
(n=2) were used as input for the WT-Ovation One-Direct system
(NuGen Technologies, Inc). All cDNA reactions were purified via Zymo
Research Clean and Concentrator
TM-25 or Qiagen RNeasy MinElute
Cleanup kits (WT-Ovation FFPE V2 and WT-Ovation One-Direct systems
respectively) as recommended. All purified cDNA probes were assessed
for quantity and quality using the Agilent 2100 Bioanalyzer and the
Nanodrop-8000 RNA Nano chips. FL-Ovation
TM cDNA Biotin Module V2
(NuGEN) was used for fragmentation and biotin labelling of 5 mgo f
cDNA and used for subsequent hybridisation to Affymetrix HGU133 Plus
2.0 microarrays.
doi:10.1371/journal.pone.0017625.g002
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distributions of the sscDNA from 500 pg or 250 pg input samples
with that derived from 50 ng RNA (Figure 3 A).
The WT-Ovation One-Direct kit is specifically intended for
amplification of RNA within the 500–10 pg range for hybridisation
to microarrays. Technical duplicates of HUVEC total RNA were
processed, reproducibly yielding dscDNA probe quantities in excess
of the 5 mg required for array hybridisation (Table 2). Compared to
the WT-Ovation FFPE RNA amplification system the cDNA
fragments generated are on average shorter with the WT-Ovation
One-Direct system suggesting less efficiency in amplification from
lower RNA input amounts (Figure 3 B). The no template control
(NTC) reaction in the WT-Ovation amplification systems areknown
to generate non-specific product in the absence of template, which
whilst this does not hybridise to Affymetrix GeneChips should be
assessed in order that non-relevant cDNA does not comprise the
major species in the hybridisation reactions (data not shown). The
extent of the non-specific amplification can be seen inthe NTC from
the WT-Ovation One-Direct system, which generated in excess of
9 mg but which appears distinct from those synthesised from
template-containing reactions with respect to size distribution and
therefore is present at such levels only in reactions with no template
(Figure 3 C). Importantly, sscDNA profiles from reactions of 10 pg
RNA input and higher are similar, yet distinct from NTC reactions.
AllsscDNAprobeswerefragmented,biotinlabelledandsubjectedto
Affymetrix GeneChip hybridisation as outlined.
Faithfulness of Microarray Measurements with minimal
total RNA input
Using the WT-Ovation FFPE system, the sscDNA probes
generated from 50 ng of input RNA result in GeneChip metrics
with 61% present calls (Table 2). Whilst these reduce as RNA input
amount reduces, they remain at an appreciably high 5160.48% for
500 pg and 47+0.04% for 250 pg input (mean 6standarddeviation).
b-actin and GAPDH 39/59 ratios (,2.57 and ,1.07 respectively)
indicate efficient amplification of the RNA template at all levels of
input with no observed 39over-bias (Table2). The impactof reducing
RNA input level on the number of probe sets detected and how this is
affected by transcript abundance can be observed by filtering probe
sets by signal intensity (Table 3). It is clear that only a small reduction
in total number of probe sets occurs with decreasing RNA input levels
and the retention of probe sets is equally high regardless of overall
abundance, as visualised by signal intensity (Table 3). The high
reproducibility of all arrays from the WT-Ovation FFPE system,
irrespective of input level, is clear from Pearson’s signal correlation
coefficients of no lower than 0.95 (M A S 5 . 0 )f o ra l lG e n e C h i p s ,a c r o s s
a 200-fold range of input RNA (Figure 4 A).
The WT-Ovation One-Direct dscDNA probes from 500 pg and
250 pg of RNA input result in present calls similar to that achieved
with the WT-Ovation FFPE system at the same overlapping input
amount (Table 2) (500 pg, 49+1.2% Vs 5160.48%; 250 pg,
45.561.1% Vs 4760.04%). Excellent concordance across probe
generation systems is further evidenced by Pearson’s signal
correlation coefficients of 0.92–0.93 (MAS5.0) at 500 pg of RNA
input and 0.91–0.92 (MAS5.0) at 250 pg (data not shown). At an
inputleveloflowerthan250 pgtheWT-OvationOne-Directsystem
resulted in approximately 39%, 35% and 18% at 100 pg, 50 pg and
10 pgrespectively(Table2).b-actin39/59 ratioarenotablyhigherin
the WT-Ovation One-Direct system compared to those obtained by
WT-Ovation FFPE, perhaps due to the shorter size distribution of
cDNAs, suggesting increased 39 over-bias and under-representation
of 59 targets (Table 2). As anticipated the non-specific product
synthesised in the NTC reaction for the WT-Ovation One-Direct
system failed to significantly hybridise to the GeneChip (Table 2,
2.3% present calls). Despite this reduction with reducing RNA input
the high reproducibility of the GeneChips from 500 pg to 50 pg in
the WT-Ovation One-Direct system can be seen in the Pearson’s
Figure 3. Bioanalyser electropherograms of cDNA probes
generated using the WT-Ovation FFPE RNA amplification
system V2 and the WT-Ovation One-Direct RNA amplification
system. cDNA quality assessed by distribution of size with the x-axis
representing polynucleotide length and the y-axis representing
arbitrary signal intensity fluorescence units. Electropherograms of
representative cDNA from each WT-Ovation system are shown. (A)
WT-Ovation FFPE system sscDNA synthesised from 50 ng of RNA is
distributed 500–1000 nucleotides. The sscDNA synthesised from 500 pg
and 250 pg of RNA input in the WT-Ovation FFPE system show a similar
distribution to the sscDNA synthesised from 50 ng of RNA. (B) The
majority of dscDNA fragments synthesised in the WT-Ovation One-
Direct system average in length at approximately 100–150 nucleotides.
RNA input level does not influence polynucleotide length (500 and
250 pg input shown). A significant difference in polynucleotide
distribution is observed in 500 pg and 250 pg input RNA reactions
depending on which WT-Ovation system used for probe synthesis. (C)
In the WT-Ovation One-Direct system, the dscDNA probes generated
from a reaction containing RNA template is distinct from that generated
in a parallel no template control.
doi:10.1371/journal.pone.0017625.g003
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(Figure 4 B). This is supported by similarities in the number of probe
sets detected as present at varying intensity levels in all Genechips
from 500 pg to 50 pg input (Table 3). It is apparent with the One-
Direct system however that a greater number of more abundant
transcripts are not detected as RNA input is further progressively
decreased (10 pg), as might be expected at this low (essentially single-
cell) level of input. The ‘‘drift’’ in GeneChip performance and RNA
targets being reliably targeted with lowering RNA template inputs
can be seen by Principle Components Analysis (Figure 4 C).
However, a significant shift in segregation is apparent when using
10 pgofinputRNAintheWT-OvationOne-Directsystem(Figure4
C), further evidenced with the Pearson’s signal correlation coefficient
falling to 0.79 (MAS5.0) (Figure 4 B).
To assess the retention of low abundant transcripts with
decreasing RNA input levels and reduced probe set detection,
microarray data was filtered for those probe sets representing a
family of proteins, G protein-coupled receptors (GPCR), which are
highly important for cellular signalling, however, known to be
generally of low abundance and notoriously difficult to detect using
microarray technology [37]. Using the WT-Ovation FFPE system
the number of probe sets detected with 50 ng of input RNA is
largely maintained when input is reduced to 250 pg (Figure 5).
These probe sets represent 56 (log2$6) and 42 (log2$7) GPCR
transcripts when using 50 ng and 52 (log2$6) and 35 (log2$7)
transcriptsfrom250 pginput (Figure 5).Significantly,the overlapof
common transcripts is impressively high, with 84% (log2$6) and
83% (log2$7) of transcripts detected at 50 ng of RNA still present
when using 200 times less input of 250 pg RNA (Figure 5). When
utilisingthepowerof the WT-Ovation One-Direct systemto further
reduce the input RNA required for microarray analysis 51 (log2$6)
and 26 (log2$7) GPCR transcripts are robustly detected at 50 pg of
input RNA, representing 74% (log2$6) and 66% (log2$7) overlap
with those detected when using 500 pg (Figure 5). Expression data
generated from 10 pg of input RNA display a reduced number of
transcripts detected (18 at log2$7), with a 34% overlap with those
detected at 500 pg input using the WT-Ovation One-Direct system
(Figure 5). However, with a less conservative signal intensity filter of
log2$6 the number of GPCR probe sets detected increases from 87
probe sets with an input of 500 pg to 98 probe sets from 10 pg
input. These 98 probe sets represent 81 genes, only 44% of which
overlap with those found at 500 pg input. It is not clear what
underpins this apparent anomaly of increased detection power with
reduced input RNA. Whilst possibly representing false positive or
inherent noise, it is also feasible that 10 pg input RNA (essentially
representing single cell analysis) results in greater accessibility of the
mRNA molecule for the subsequent enzymatic steps in the sscDNA
generation procedure, at least for this class of transcripts.
Effect of probe generation method on microarray
performance of vascular endothelial biopsy samples
In order to determine the preferred approach for microarray
analysis using vascular endothelial biopsies, RNA derived from a
representative test sample was equally split and processed through
both the WT-Ovation FFPE RNA amplification system V2 and the
WT-Ovation One-Direct RNA amplification system. An input level
of 300 pg of total RNA was chosen to allow comparison of both
systems. Resultant yields of cDNA probe obtained from 300 pg of
input RNA were 4.3 mga n d1 1 . 9mg in the WT-Ovation FFPE and
WT-Ovation One-Direct systems, respectively (Table 4). The
sscDNA obtained using the WT-Ovation FFPE system fails to reach
therecommended5 mgofprobeforfragmentationandhybridisation
to Affymetrix GeneChips. The quality of the cDNA probes
synthesised from both systems also displayed a reduction in size
distribution when using clinical sample RNA compared to HUVEC
RNA, associated with reduced efficiency of RNA amplification
Table 2. Quality metrics of cDNA probes generated from titrated HUVEC RNA using WT-Ovation FFPE and WT-Ovation One-Direct
RNA amplification systems and hybridised to Affymetrix Human Genome U133 Plus 2.0 Arrays.
Amplificationkit RNA input (pg) cDNA yield (mg)
cDNA probe processed
for GeneChip (mg) % P calls b-actin 39/59 ratio
FFPE 50000 9.93 5 61.0 1.95
FFPE 500 a 9.63 5 51.5 2.31
FFPE 500 b 9.39 5 50.9 2.28
FFPE 250 a 6.23 5 47.3 2.36
FFPE 250 b 8.32 5 47.3 2.57
One-Direct 500 a 16.27 5 50.0 5.87
One-Direct 500 b 16.33 5 48.3 4.27
One-Direct 250 a 17.19 5 46.6 4.61
One-Direct 250 b 14.47 5 44.4 4.58
One-Direct 100 a 14.78 5 38.9 4.30
One-Direct 100 b 13.69 5 39.2 4.01
One-Direct 50 a 13.99 5 34.0 4.91
One-Direct 50 b 13.99 5 36.0 3.01
One-Direct 10 a 13.62 5 19.2 7.21
One-Direct 10 b 13.18 5 18.3 5.30
One-Direct NTC 9.36 5 2.3 5.87
RNA input, cDNA yield and mean quality metrics for microarrays following hybridisation of 5 mg of cDNA probes generated from either WT-Ovation FFPE or One-Direct
RNA amplification systems. Quality metrics reflect Expression Console (Affymetrix) report data generated following MAS5.0 feature extraction. NTC = no template
control. Technical duplicates were performed for each.
doi:10.1371/journal.pone.0017625.t002
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3.2 mgofcDNAprobewasused fromeachsystemforfragmentation,
labelling and hybridisation. In addition, a second hybridisation
containing the recommended 5 mg of dscDNA from the WT-
Ovation One-Direct kit was carried out as a further control. Despite
the lower amount of cDNA probe hybridised, the WT-Ovation
FFPE kit performed well by generating GeneChip quality metrics
which include 30.5% present calls (Table 4). In contrast, the cDNA
probe hybridised from the WT-Ovation One-Direct kit at both
3.2 mga n d5 mg failed to produce % present calls of above
background level of hybridisation achieved byNTC (Table 4). Based
on cDNA size distribution and subsequent microarray quality
metrics the WT-Ovation FFPE system was chosen as the preferred
technology for global transcriptomics of vascular endothelial biopsies
collected and processed under the current conditions.
Efficacy of cDNA probe generation from vascular
endothelial biopsy samples
sscDNA probe generation using the WT-Ovation FFPE RNA
amplification system V2 was carried out using RNA from vascular
endothelial cell biopsy samples, with all inputs normalised to 300 pg
RNA. With the assumption of an RNA content of 8 pg/cell, this
equates to our global profiling being performed on the RNA
equivalent of 37 purified endothelial cells. Whilst it is possible to
generate array datasets from this range of input RNA material
without the requirement to normalise RNA input for all samples,
data outlined here clearly demonstrate that omission of normalisa-
tion of input quantities would likely introduce further magnitudes of
variability (Figure 4 C). To maximise ability to capture of variability
accounted for primarily by biological factors only, it was considered
prudent to normaliseinput RNAs of all samples prior to arrayprobe
generation. The numbers of samples achieving the 300 pg RNA
yield was 93 out of 114 (81.6%). sscDNA probes were generated in
batches according to kit size (to avoid freeze-thaw cycles) and
included a 50 ng and 300 pg HUVEC RNA positive control for
each batch, together with a NTC. A summary of yields and quality
of resultant sscDNA probes is outlined in Table 5. The yield from
the NTC reactions consistently generated ,3 mg of sscDNA, within
the manufacturer’s guidelines (Figure 7 H).The sscDNA yieldsfrom
the 50 ng and 300 pg HUVEC RNA positive controls were in
excess of the 5 mg typically required for GeneChip hybridisation.
Quality assessment by Agilent Bioanalyzer shows that the sscDNA
fragments generated from the 50 ng and 300 pg of HUVEC RNA
positive controls were of broad distribution in length, averaging
approximately 500–1000 nucleotides, suggesting efficient sscDNA
synthesis (Figure 7 A, B). The average yield across all 93 clinical
samples was 6.8661.89 mg of sscDNA remaining following quality
control assessment (Table 5). Of the 93 clinical samples utilised,
86% yielded over 5 mg considered the maximum probe required to
proceed to hybridisation to GeneChips. Reducing the amount of
sscDNA probehybridisedto the GeneChipsto 4.5 mg was chosento
represent a balance between maximal cohort inclusion (91%)
without significantly negatively impacting array quality.
A broad spectrum of sscDNA quality derived from vascular
endothelial RNA was observed, with the size distribution of some
cDNAs peaking at 500–1000 nucleotides as would be expected for
highest quality probes, but others generated sscDNA peaking at
less than 500 nts, representing less efficient synthesis. Twenty-one
of the sscDNAs displayed a high level of short fragments (,200
nucleotides) deemed as non-specific amplification and failed to
display a significant amount of efficient and template specific
amplification so were not hybridised to GeneChips (Figure 7 G).
By visual inspection of the 64 remaining sscDNA sample
electropherograms an sscDNA quality score of 1–4 was attributed,
based on average size distribution and extent of overlay with
positive control electropherograms, with ‘‘1’’ representing highest
quality (Figure 7 C–F). All cDNA probes were fragmented and
biotin-labelled in preparation for hybridisation and all resulted in
fragments of ,50–200 nt (data not shown), as expected [36].
Microarray performance of vascular endothelial biopsy
samples
Mean array quality control metrics were assessed for all 64
vascular endothelial biopsy samples hybridised to GeneChips.
Mean % present calls of 32.0%67.21% (mean 6 SD) (Table 6)
were achieved along with good control metrics such as background
(29.661.28) and noise (0.8660.09) suggesting efficient and
consistent hybridisation of all arrays (Table 6). These were also
Table 3. Impact of decreasing RNA input amounts on overall probe sets detected at varying transcript abundances by the
WT-Ovation FFPE and WT-Ovation One-Direct RNA amplification systems.
Signal Intensity Ovation-FFPE 50 ng 500 pg 250 pg
Log2.5 30982 30471 30088
Log2.6 24190 23416 22863
Log2.7 18758 18266 18011
Log2.8 13684 13303 13240
Log2.9 9076 8667 8651
One-Direct 500 pg 250 pg 100 pg 50 pg 10 pg
Log2.5 31648 31593 31813 32612 42023
Log2.6 22854 22352 21360 20256 20269
Log2.7 17362 17003 16254 15401 10855
Log2.8 12664 12514 12055 11753 7809
Log2.9 8518 8433 8263 8248 5887
The number of probe sets detected at each signal intensity level (as a measure of transcript abundance) is shown. Numbers are the mean of duplicate arrays for input of
500 pg and below. Reduction of input RNA amounts has a minimal impact on the overall numbers of probe sets detected, but which is more evident with the One-
Direct system, with a greater number of more abundant transcripts not being detected with decreasing RNA input.
doi:10.1371/journal.pone.0017625.t003
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synthesised using the NuGen WT-Ovation RNA amplification systems and the effect of reducing RNA input on the resultant
Affymetrix GeneChips. (A)R
2 values generated when comparing one GeneChip from 50 ng of input HUVEC RNA and duplicate GeneChips from
500 pg and 250 pg of input HUVEC RNA using MAS5.0 analysed data by Pearson’s correlation of signal. (B) Duplicate GeneChips from 500 pg,
250 pg, 100 pg, 50 pg and 10 pg RNA input compared using MAS5.0 analysed data by Pearson’s correlation of signal. C. Principal Component
Analysis of all probe sets from GeneChips hybridised with cDNA probes from either WT-Ovation FFPE or WT-Ovation One-Direct RNA amplification
systems.
doi:10.1371/journal.pone.0017625.g004
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GAPDH 39/59 ratios of 1.5961.21 suggesting high quality and
efficient amplification of RNA (Table 6). Principle Component
Analysis of all quality control metrics following MAS5.0 feature
extraction was carried out (Figure 8 A). In concordance with the
MAQC established framework [38], designed to increase the
consistency of microarray datasets, the majority of arrays in this
study cluster within 2 standard deviations when assessed by quality
metrics (Figure 8 A). Those arrays lying outside the 2 SD range
were explained by either (a) high housekeeping gene 3–59 ratios,
suggesting reduce probe amplification efficiency or (b) lower signal
intensity/lower spike-in control signal suggesting less efficient
hybridisation. These ‘‘outlier’’ arrays samples remain out with the
group clusters whether using all QC metrics, array AFFX control
probes only or when using all probes (Figure 8 A, B, C). Principles
component analysis focusing on the GeneChip control probes only
demonstrates the lack of distinct populations of GeneChips caused
by any experimental factors (Figure 8 B), providing evidence for
the positive impact of the controlled reduction of variation
introduced by technical parameters. Colouring of these data points
Figure 5. Low abundant probeset retention with decreasing RNA input levels. Data from the microarrays generated according to the
workflow set out in Figure 2 was filtered for those probe sets representing a family of proteins, G protein-coupled receptors (GPCR), known to be of
low abundance and difficult to detect using microarrays. The signal intensity was set at a threshold of Log2$6 or Log2$7 to ensure analysis of probe
sets demonstrating strong hybridisation and robust signal. Data plotted is the number of GPCR probe sets present with differing RNA input levels and
the number of genes that are represented in parenthesis below the data point. When duplicate GeneChips were available only the probe sets passing
threshold in both duplicates were included. Venn diagrams illustrate the overlap of common genes between GeneChips from titrated RNA input
levels for either WT-Ovation FFPE or WT-One-Direct RNA amplification systems.
doi:10.1371/journal.pone.0017625.g005
Global Transcriptomics from Minimal Input RNA
PLoS ONE | www.plosone.org 9 March 2011 | Volume 6 | Issue 3 | e17625by sscDNA quality however clearly illustrates the impact of this
factor on variability within the dataset (Figure 8 B). Nonetheless,
Figure 8C demonstrates clear segregation and capturing of
biological variability between two of the sample groups studied
here, the results of which will be presented in detail elsewhere.
Discussion
A great deal of progress has been made over the past few years
in reducing the amount of input material required to carry out
global transcriptional profiling using microarray technology.
There are several reports of microarray datasets produced using
laser capture micro-dissected material and from clinical biopsies
which have yielded only nanograms of RNA material [19,22].
However, there are few reports of successful global transcriptomics
using input RNA within the picogram range [17,24,27,39]. In
addition, many of these reports are based on the titrated dilution of
stock RNA solutions and not the ‘‘field’’ requirement of robust and
successful arrays subsequent to recovery of picograms of RNA
from minimal cell numbers [17,24]. There are cases, such as in
this study, where a clinical biopsy yields material estimated to be
,1000 cells [29], making recovery of adequate amounts of RNA
and subsequent transcriptional profiling significantly challenging.
RNA extraction methods shown to successfully yield good
quality RNA of sufficient amounts from thousands or millions of
cells are of course not necessarily optimised for use when using
Table 4. Quality metrics from test vascular endothelial biopsy sample cDNA probes generated by the WT-Ovation FFPE and WT-
Ovation One-Direct RNA amplification systems.
Amplification kit cDNA probe yield (mg)
cDNA probe processed for
GeneChip (mg) % P calls b-actin 39/59 ratio
FFPE 3.2 3.2 30.5 4.50
One-Direct 10.7 3.2 2.4 35.68
One-Direct 10.7 5 2.7 43.90
cDNA yield and microarray quality metrics generated from one vascular endothelial cell biopsy using either the WT-Ovation FFPE or One-Direct RNA amplification
system. Quality metrics reflect Expression Console (Affymetrix) report data generated following MAS5.0 feature extraction.
doi:10.1371/journal.pone.0017625.t004
Figure 6. Bioanalyser electropherograms of cDNA probes synthesised by the WT-Ovation FFPE RNA amplification system V2 and
the WT-Ovation One-Direct RNA amplification system using a vascular endothelial cell biopsy sample. cDNA quality assessed by
distribution of size with the x-axis representing polynucleotide length and y-axis representing arbitrary signal intensity fluorescence units. Using a
vascular endothelial cell biopsy sample a shift to shorter cDNA lengths is apparent compared to 500 pg total HUVEC RNA input in both the (A) WT-
Ovation FFPE RNA amplification system V2 and the (B) WT-Ovation One-Direct RNA amplification system. NTC = no template control.
doi:10.1371/journal.pone.0017625.g006
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traditional RNA extraction workflows to have a detrimental effect
on RNA yield from minimal cell numbers, for example passing cell
lysates through homogenisation matrices or carrying out on-
column DNAse I treatments. The negative impact of these
workflow components on RNA yield becomes evident only when
using lower amounts of starting material. However, by altering
these workflows and using titrated cell numbers we have succeeded
in establishing an optimal RNA extraction process which yields
approximately 2.5 times higher RNA yields when utilising below
3000 cells. Isolating RNA from cell populations such as these is
challenging and whilst an average estimate of RNA content per
cell may be in the range of 10 pg, depending on the cell type, is
still not guaranteed to yield amounts of RNA within the nanogram
range. To ensure maximum exploitation of the minimal cell
samples available to us, we also sought to establish an RNA
amplification method capable of producing robust array hybrid-
isation probes, resulting in data capable of capturing biological
information of interest, from RNA within the picogram range.
The WT-Ovation FFPE RNA amplification system is specifi-
cally designed for use with RNA of reduced integrity from FFPE
material. This system employs random priming in addition to
PolyA priming and incorporates a secondary SPIA linear
amplification step. In this study we proposed to exploit this
increased amplification power for use with minimal input RNA
amounts extracted from any tissue matrix. The FFPE system
demonstrated that 250 pg of input RNA yields the same high
quality cDNA probes and GeneChips with high correlation
(R2.0.95) to those obtained using 50 ng of input RNA. This
translated to retention of 84% of the genes detected at 50 ng input
remaining as a robust signal at 250 pg input when studying a
family of genes (GPCRs) known to be of low abundance and
difficult to detect by conventional microarray analysis. When
processing clinical biopsies containing minimal cell numbers good
quality cDNA and array metrics were obtained, although a
reduction in sscDNA yield was observed. However, this reflected
loss of synthesised material rather than poor overall synthesis,
resulting from sscDNA purification schema employed at that time
and which has since been changed to an alternative.
Further opportunity for increased amplification power when
using RNA input within the picogram range is offered by the One-
Direct RNA amplification system, designed for use with high
quality RNA ranging from 500 pg down to 10 pg of input. We
assessed this using titrated high quality RNA within the kits
working range and found that reducing RNA input in this kit does
not influence the quality of cDNA probe generated, with all
samples from 500 pg to 10 pg producing similar populations of
cDNA probe size distribution. The cDNA probes generated at all
input levels using the One-Direct system did consist of shorter
probe fragments than those generated from at little as 250 pg
using the FFPE system. However, this does not appear to
significantly affect the performance of the subsequent microarrays
as illustrated by the similarities in the microarray metrics from the
FFPE and One-Direct system at the same levels of input RNA.
Within the One-Direct system high correlation between Gene-
Chips from decreasing input material can been seen from 500 pg
down to 50 pg of input (R2.0.92). Unfortunately, as might be
expected we did not observe this high level of performance when
using 10 pg of input RNA as these samples generate R2 values of
0.77–0.86 when compared to higher input levels, with apparent
loss of detection of higher abundance transcripts. We conclude
therefore that the One-Direct system can further push the lower
limits of material required for probe synthesis for microarray
experiments to 50 pg of input when using high quality RNA,
without significant impact on resulting information generated.
Nonetheless, 10 pg of input RNA still results in generation of
arrays from which a large amount of transcriptional information
can be derived (approximately 19% present calls). However, it
should be noted that variation in input RNA results in differences
in the transcriptional information captured by array, and which is
particularly evident at low input levels. Therefore, whilst
quantification of such low levels following primary RNA isolation
is challenging, we recommend that this is performed to allow
subsequent input normalisation (as outlined in the current study)
and eventual maximisation of ability to interrogate variability due
to biology rather than technical parameters.
Whilst not exploited here, a further distinct advantage of the
One-Direct system is the option of preparing microarray probes
directly from cell lysis of minimal cell numbers without prior RNA
purification. The capability of direct cell lysis has the potential to
negate the need for RNA extraction and avoid the inevitable loss
of RNA accompanying these workflows. However, RNA extrac-
tion methods specifically optimised for minimal cell numbers
remain relevant as not all collection techniques provide the
material in the appropriate conditions/volume required for this
direct cell lysis step. For example, the vascular endothelial cell
biopsies used in this study require an immuno-bead positive
enrichment stage within the cell collection workflow involving a
higher liquid volume than that required to commence the One-
Direct system at the cell lysis stage. Future efforts will focus on
alternative endothelial cell collection schema to exploit the low
working range of the One-Direct kit. Following on from our work
with the One-Direct system using high quality RNA at 50 pg or
Figure 7. Assignment of ‘‘quality score’’ to sscDNA probes. Quality scores of 1–4 for sscDNA were assigned following visual assessment of
distribution of polynucleotide size, with representative electropherograms shown here. (A) sscDNA synthesised from 50 ng total HUVEC RNA
represents an amplification positive control of highest quality achievable. (B) sscDNA synthesised from 300 pg total HUVEC RNA amplification
positive control of highest quality that could be expected from 300 pg of input RNA. (C–G) sscDNA synthesised from 300 pg of total RNA from a
vascular endothelial biopsy sample. sscDNA has a electropherogram similar to that seen in the positive controls, peaking at over 500 nts and so was
attributed a cDNA quality of 1 (C). sscDNAs progressively shorter in size distribution were designated quality scores of 2, 3 or 4 (D–G). sscDNAs
designated lowest quality and therefore not hybridised to GeneChips (C) were of predominantly ,200 nts in length. (H) No template control (NTC).
doi:10.1371/journal.pone.0017625.g007
Table 5. sscDNA probe yields for vascular endothelial biopsy
samples, titrated HUVEC RNA positive controls and NTC’s
synthesised using the WT-Ovation FFPE RNA amplification
system.
Sample Type sscDNA yield(mg) SD
50 ng HUVEC (n=10) 18.52 1.76
300 pg HUVEC (n=10) 9.12 2.49
NTC (n=10) 1.32 0.20
Biopsy samples (n=93) 6.86 1.89
Mean yields after quantification of sscDNA generated from vascular endothelial
biopsy samples (n=93). Positive control reactions using RNA input of 50 ng or
300 pg of HUVEC total RNA were run along side all batches of cDNA probe
synthesis (n=10). In each batch there was also a no template control reaction
included. SD = Standard deviation.
doi:10.1371/journal.pone.0017625.t005
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minimal cell samples with direct cell lysis we believe that this
technology not only further lowers the limits of input material
needed to carry out microarray experiments but also increases the
sample types which can be robustly interrogated by global
expression profiling. Nonetheless, based on our observations here,
it is still desirable if possible to begin with a known, normalised,
amount of input RNA, such that inherent variation is limited to
that of biological origin.
Similarly, we believe that assessment of the performance of
array probe generation workflows using control RNA titrations
rather than bona fide material of interest do not always realistically
mirror the experimental conditions which will be met.
Due to the successful performance of the FFPE system and the
majority of clinical samples yielding over the lower limit of 250 pg
input RNA with this system we processed our vascular endothelial
cell biopsies on to microarrays. The average percentage of present
calls on these GeneChips was 32%, along with acceptable quality
for all other control metrics. Whilst still representing a relatively
high number of transcripts being interrogated, this percentage of
present probes is lower than we would expect when using titrated
good quality RNA to the same low levels. Previous reports have
suggested that samples of ,1000 cells can only generate reliable
expression data for the most abundantly expressed genes, thereby
leading to a biased dataset [40]. Importantly, we have demon-
strated here that the number of probe sets detected shows a high
level of retention with lowering RNA input levels in two different
probe generation methods, impacting only the most abundant
transcripts at low input levels in the One-Direct system.
In the present study we have established an RNA extraction
method specifically designed to isolate the maximum RNA from
minimal cell numbers, and have utilised recent developments in
isothermal linear amplification methods to generate reliable and
robust microarray data from these minimal cell clinical samples,
which we estimate to have been perfomed on the RNA equivalent
of approximately 37 cells. Several reports have supported the use
of an isothermal amplification technique for cDNA probe
generation for use with microarrays [17,24,27,35,36]. These have
included reports for diluted RNA down to 250 pg of RNA input
[24,39]. This study has further advanced these findings by
demonstrating the use of WT-Ovation technology at low levels
of input to generate a dataset of global transcriptional profiling
from clinical samples following RNA extraction from minimal cell
numbers. Our work with the One-Direct RNA amplification
system suggests that this lower limit of input can now be further
reduced to 50 pg of good quality RNA without obvious impact on
data quality or loss of lower abundant genes and can be utilised at
10 pg input RNA, albeit with expected and accepted loss of
transcriptome information. The One-Direct system may be
exploitable for some clinical sample types by using the direct cell
lysis workflow offered to eradicate the need for RNA extraction
workflows. We also demonstrate the successful global transcrip-
tional profiling of biopsies containing minimal cell numbers which
have previously been limited to focussed transcriptional interro-
gation. Whilst we have not embarked here on formal validation of
identified transcriptional differences to demonstrate the validity of
our methodologies as has been done by others [39], our analysis
strategy of utilising the entire transcriptome to inform correlation
co-efficients rather than filtered gene sets has been previously
demonstrated to be optimal [39]. Furthermore, the transcriptional
changes we have observed here are greater than 5000 which pass
multiple test correction and two-fold change filtering, as evidenced
by the striking separation of phenotypic groups in PCA. In our
experience of post-array confirmation of similar sets of targets
derived from sscDNA-based microarray studies, we have been
able to confirm by qPCR the vast majority of these. Additionally,
our analyses here suggest the ability of these procedures to allow
interrogation of classes of rare transcripts, even at impressively low
input RNA amounts, for which microarray technology is widely
believed to be insufficiently sensitive. The ability to interrogate the
global transcriptome of clinical samples containing limited cellular
material has the potential to allow molecular profiling endeavours
from previously inaccessible sources.
Methods
Cell culture
Low passage Human umbilical venous endothelial cell line
(HUVEC) was obtained from Millipore and were maintained in
EGM-2 BulletKit medium (Lonza, USA) according to the
manufacturers recommendations at 37uCi n5 %C O 2 and 100%
humidity. Cells were harvested and counted following growth to
,80% confluency. Briefly, the media was removed from the flask
and the cell monolayer was washed by pipetting 1 x HEPES
Buffered Saline Solution (Lonza, USA) over the cells. Following
removal of the 1 x HEPES Buffered Saline Solution, 1 ml of
160.05% Trysin/EDTA solution (Sigma-Aldrich) was added to
the flask. Cells were loosened by placement in the incubator for 1
minute followed by the addition of 1 x Trypsin Neutralizing
Solution and then suspension in 1 x HEPES Buffered Saline
Solution. The cell suspension was centrifuged for 5 minutes at
220 x g and the cell pellet resuspended in 1 x HEPES Buffered
Saline Solution. Following a second centrifugation the cell pellet
was resuspended in fresh 1 x HEPES Buffered Saline Solution.
Cell counting
Four 200 ml aliquots of the cell suspension were removed to
1.5 ml tubes. To each aliquot 200 ml of Solution A-100
(Chemometec A/A, Denmark) was added and each tube vortexed
for 30 seconds. 200 ml of Solution B-100 was then added to each
tube followed by vortexing for 30 seconds. The cell solution was
analysed by a NucleoCounter (ChemoMetec A/S) following
loading of each sample in to a Cell Counting Cartridge. All
samples were counted for cell number in quadruplicate and
diluted in 1 x HEPES buffer to the desired cell number (ranging
from 3000 to 200 cells) in a final volume of 50 ml. To each 50 ml
Table 6. Quality metrics following hybridisation of sscDNA probes from vascular endothelial biopsy samples to Affymetrix Human
Genome U133 Plus 2.0 arrays.
Average Background Average Noise Scaling factor % P calls b-actin 39/59 ratio GAPDH 39/59 ratio
Clinical samples
(n=64)
29.661.3 0.8660.1 3.7461.9 32.0367.2 2.6161.1 1.5961.2
Quality metrics reflect Expression Console (Affymetrix) report data generated following MAS5.0 feature extraction. Values are mean 6 standard deviation.
doi:10.1371/journal.pone.0017625.t006
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mercaptoethanol (Qiagen) was added and all samples stored at
280uC prior to processing.
Vascular endothelial biopsies
Venous endothelial cells were collected from healthy controls,
patients with insulin resistance and coronary artery disease. The
study was approved by the Tayside committee on Medical Ethics.
All patients gave written informed consent and all experiments
were carried out in accordance to the Helsinki Declaration.
Endothelial cells were collected after the volunteer had been laid
supine for 30 minutes using a modified technique of venous
endothelial biopsy as described by [29]. A 0.46 mm ‘‘J’’ tip Spring
Wire Guide with Arrow Advancer (ARROW, Arrow International
Inc., Germany) was used for EC sampling. Each wire was
advanced through an 18 G cannula positioned in the forearm
vein. The tip was advanced 10 cm and moved to and fro several
times within the vein. The distal portion of the wire was then
transferred to a 15 ml conical tube containing dissociation buffer
(0.5% bovine serum albumin, 2 mM EDTA and 100 mcg/ml
heparin in PBS, pH 7.4), kept at 4uC. Cells were removed from
the distal portion of the wire by insertion into the ‘‘flush system’’,
attachment of syringes containing dissociation buffers (ECDS).
This process was repeated for each wire using the same buffer
contained within the syringe.
Endothelial Cell separation
Each sample was split between 4 eppendorf tubes (approx
500 ml/tube) and 5 ml of dynabeads (Dynal Biotech Inc), pre-
coated with mouse anti-human CD146 monoclonal antibody
(Clone MAB16985, Millipore), was added to each tube. The tubes
were incubated at 4uC for 25 mins with rotation before being
placed in a magnetic rack. A magnet was used to collect the beads
and the supernatant removed and discarded. The remaining beads
were then washed twice with sterile ECDS (500 ml per wash), once
with 500 ml sterile Hanks Balanced Salt Solution (HBSS) and twice
with sterile Phosphate Buffered Saline (PBS) (500 ml per wash).
After the first PBS wash the supernatant was discarded but after
the second, approximately 50 ml of liquid was retained to
resuspend the beads. Buffer RLT/2-mercaptoethanol (Qiagen,
UK) was added to the bead suspension. Brief vortexing to disrupt
the cells from the beads and then separation by 2 minutes on the
magnet was carried out. Finally, the resultant lysate was
transferred to a fresh, sterile eppendorf tube and stored at
280uC. The entire cell separation procedure was completed
within 1 hour of venous cell biopsy.
Total RNA isolation
Total RNA was isolated from 1610
6 HUVEC using the
RNeasy Mini RNA isolation kit (Qiagen) according to manufac-
turer’s instructions. Briefly, 350 ml HUVEC lysate samples were
thawed following storage at 280uC. To ensure complete cell lysis
the samples were vortexed vigorously for 10 seconds and pulse
spun. An equal volume (350 ml) of 70% ethanol was added to the
cell lysate and mixed by pipetting. The entire sample was applied
Figure 8. Assessing GeneChip quality control metrics and the
effects of cDNA probe quality using Principle Components
Analysis. (A) MAS5.0 QC data generated in Expression Console
(Affymetrix) displayed using PCA illustrates the majority of GeneChips
(n=64) clustering together within 2 standard deviations of the group
mean. The PCA is coloured according to the sscDNA quality score
designated to each sample. Of the small number of samples lying out
with the 2 SD boundary, sscDNA quality does not appear to be
responsible for the variation shown, with this being contributed by
other experimental factors. (B) PCA visualisation of Affx control probes
only, coloured by sscDNA quality score shows that a significant
proportion of the variation is driven by quality of the sscDNA probes.
(C) PCA visualisation including all probes reveals the distinct sub-
groups of the cohort according to expressed transcriptome patterns,
regardless of cDNA quality.
doi:10.1371/journal.pone.0017625.g008
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RNeasy Mini Spin Columns were centrifuged for 15 seconds at
16,300 x g. The flow-through was re-applied to the same RNeasy
Mini Spin Column and the centrifugation repeated. 350 mlo f
buffer RW1 was applied to each RNeasy Mini Spin Columns
followed by centrifugation for 15 seconds at 16,300 x g. A DNase I
incubation mix was prepared by combining 10 ml of DNase I and
70 ml of Buffer RDD per sample. DNase treatment was performed
by pipetting 80 ml of DNase I incubation mix directly on to the
RNeasy Mini Spin column membrane and incubating at room
temperature for 15 minutes. To wash the RNeasy Mini Spin
Column, 350 ml of Buffer RW1 was added and centrifuged for 15
seconds at 16,300 x g followed by 500 ml of Buffer RPE and
centrifugation for 2 minute at 16,300 x g. An additional
centrifugation for 1 minute at 16,300 x g was carried out to dry
the column membrane. RNA was eluted into fresh 1.5 ml
microcentrifuge tubes using 50 ml of RNase-free water followed
by centrifugation for 1 minute at 16,300 x g.
When isolating RNA from titrated minimal cell numbers (3000
– 200) total RNA was isolated using the RNeasy Micro RNA
isolation kit (Qiagen) following the manufacturers instructions
(process A) or with modifications (process B) (Figure 1A). RNA
isolation from vascular endothelial biopsies was also carried out
using the RNeasy Micro RNA isolation kit (Qiagen) following
process B (Figure 1A).
When following the manufacturer’s instructions (process A) the
cells were suspended and lysed by vortexing vigorously for 10
seconds and pulse spun. Sample were homogenised by pipetting
the cell lysate directly onto a QIAshredder Spin Column (QIagen)
placed in a 2 ml collection tube and centrifuged for 2 minutes at
16,300 x g. An equal volume (350 ml) of 70% ethanol was added to
the cell lysate and mixed by pipetting. The entire sample was
applied to an RNeasy MinElute Spin Column in a 2 ml collection
tube. The RNeasy MinElute Spin Columns were centrifuged for
15 seconds at 16,300 x g. The flow-through was re-applied to the
same RNeasy MinElute Spin Column and the centrifugation
repeated. 350 ml of buffer RW1 was applied to each RNeasy
MinElute Spin Column followed by centrifugation for 15 seconds
at 16,300 x g. A DNase I incubation mix was prepared by
combining 10 ml of DNase I and 70 ml of Buffer RDD per sample.
DNase treatment was performed by pipetting 80 ml of DNase I
incubation mix directly on to the RNeasy Mini Spin column
membrane and incubating at room temperature for 15 minutes.
To wash the RNeasy Mini Spin Column, 350 ml of Buffer RW1
was added and centrifuged for 15 seconds at 16,300 x g followed
by 500 ml of Buffer RPE and centrifugation for 15 seconds at
16,300 x g. A further 500 ml of 80% Ethanol was added and the
column centrifuged for 2 minutes at 16,300 x g. An additional
centrifugation for 5 minutes at 16,300 x g was carried out to dry
the column membrane. RNA was eluted into fresh 1.5 ml
microcentrifuge tubes by adding 20 ml of RNase-free water on to
the membrane followed by centrifugation for 1 minute at 16,300
x g. The eluate was reapplied to the same RNeasy MinElute Spin
Column and the centrifugation repeated. All samples were stored
at 280uC prior to further processing.
Total RNA from minimal cell numbers was also extracted using
the RNeasy Micro RNA isolation kit with the following
modifications (process B) (Figure 1A). Cells were suspended and
lysed by vortexing vigorously for 10 seconds and pulse spun. An
equal volume (350 ml) of 70% ethanol was added to the cell lysate
and mixed by pipetting. The entire sample was applied to an
RNeasy MinElute Spin Column in a 2 ml collection tube. The
RNeasy MinElute Spin Columns were centrifuged for 15 seconds
at 16,300 x g. The flow-through was re-applied to the same
RNeasy MinElute Spin Column and the centrifugation repeated.
700 ml of buffer RW1 was applied to each RNeasy MinElute Spin
Column followed by centrifugation for 15 seconds at 16,300 x g.
To wash the RNeasy MinElute Spin Column, 500 ml of Buffer
RPE was added and centrifuged for 15 seconds at 16,300 x g
followed by 500 ml of 80% Ethanol and centrifugation for 2
minute at 16,300 x g. An additional centrifugation for 5 minutes at
16,300 x g was carried out to dry the column membrane. RNA
was eluted into fresh 1.5 ml microcentrifuge tubes by incubating
20 ml of RNase-free water on the membrane for 1 minute followed
by centrifugation for 1 minute at 16,300 x g. The eluate was
reapplied to the same RNeasy MinElute Spin Column and the
incubation and centrifugation repeated.
Genomic DNA (gDNA) elimination was carried out on the total
RNA samples from minimal cell numbers by gDNA Wipeout
buffer treatment (Quantitect Reverse transcription kit, Qiagen).
Firstly, the 20 ml RNA samples were dried down in a Concentrator
5301 (Eppendorf) without heat for 9 minutes to obtain a final
volume of 12 ml. To each concentrated RNA sample 2 mlo f
gDNA Wipeout buffer was added and incubated at 40uC for 5
minutes.
Total RNA was recovered from the gDNA elimination reaction
using the RNeasy Micro kit (Qiagen) RNA clean up protocol.
Briefly, 86 ml of RNase-free water was added to the gDNA
elimination reactions. 350 ml of buffer RLT/2-mercaptoethanol
was added and mixed by pipetting. 250 ml of 100% Ethanol was
added and mix by pipetting. The entire sample was applied to an
RNeasy MinElute Spin Column in a 2 ml collection tube. The
RNeasy MinElute Spin Columns were centrifuged for 15 seconds
at 16,300 x g. The flow-through was re-applied to the same
RNeasy MinElute Spin Column and the centrifugation repeated.
500 ml of buffer RPE was applied to each RNeasy MinElute Spin
Column followed by centrifugation for 15 seconds at 16,300 x g.
To wash the RNeasy MinElute Spin Column, 500 ml of 80%
Ethanol and added and the columns centrifuged for 2 minute at
16,300 x g. An additional centrifugation for 5 minutes at 16,300
x g was carried out to dry the column membrane. RNA was eluted
into fresh 1.5 ml microcentrifuge tubes by incubating 20 mlo f
RNase-free water on the membrane for 1 minute followed by
centrifugation for 1 minute at 16,300 x g. The eluate was reapplied
to the same RNeasy MinElute Spin Column and the incubation
and centrifugation repeated. All samples were stored at 280uC
prior to further processing.
Total RNA quantification
The quantity of total RNA from 1610
6 HUVEC was measured
using a Nanodrop ND-8000 spectrophotometer (Nanodrop
Technologies, Wilmington, DE). RNA quality was assessed in
part by OD260/280 ratios but primarily by use of an Agilent 2100
Bioanalyzer (Agilent Technologies, Palo Alto, CA).
The quantity of total RNA from titrated minimal cell numbers
and vascular endothelial biopsies was measured following reverse
transcription of the RNA to cDNA and subsequent real-time
quantitative PCR along with a calibration curve of RNA from the
same cells. RNA reverse transcription was carried out using the
Quantitect Reverse Transcription Kit (Qiagen) following the
manufacturers instructions. Briefly, both unknown samples and
standard curve samples made from HUVEC RNA dilutions of
known concentration ranging from 500 ng–1 pg RNA were made
up to 12 ml volume using RNase-free water. When measuring
RNA quantity from HUVEC titrated minimal cell numbers, all of
the isolated RNA was used in the Quantitect Reverse Transcrip-
tion Kit (Qiagen). Following RNA isolation optimisation using
either HUVEC titrated minimal cell numbers or vascular
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transcription. gDNA Wipeout buffer (7 x) was added to each
sample and mixed by pipetting. All samples were incubated at
42uC for 5 minutes and placed immediately on ice. A reverse
transcription reaction was carried out by adding 1 mlo fR T
enzyme, 4 ml of Quantiscript buffer (5 x) and 1 ml of RT primer
mix to each sample followed by incubation at 42uC for 20 minutes.
The reaction was halted by a further incubation at 95uC for 3
minutes. All reaction were stored at 220uC prior to further
processing.
Quantitect cDNA samples generated from minimal cell
numbers and vascular endothelial biopsies or standard curve
RNA dilutions were diluted 1:25 or 1:100, respectively for input in
the real-time quantitative PCR. All quantification was carried out
using b-actin as the target gene for amplification. SybrGreen (Bio-
rad) along with b-actin primers used for quantification of HUVEC
titrated minimal cells and vascular endothelial cell biopsy samples.
Forward primer: 5-GGACTTCGAGCAAGAGATGG-3 and
Reverse primer: 5-AGCACTGTGTTGGCGTACAG-3. PCR
master mix was loaded to each well and the plate centrifuged at
2,000 x g for 20 seconds and run on a 7900HT (ABI).
Microarray probe generation
Preparation of cDNA SPIA probes for microarray hybridisa-
tion, was carried out with varying amounts of total HUVEC RNA
(50 ng–10 pg) or vascular endothelial cell samples using NuGEN
Technologies (California, USA) WT-Ovation
TM FFPE RNA
amplification system V2 or WT-Ovation
TM One-Direct RNA
amplification system according to the manufacturers’ instructions.
cDNA probes generated using the WT-Ovation
TM FFPE RNA
amplification system V2 from RNA isolated from titrated minimal
cell samples were purified prior to quantification using either the
DNA clean and concentrator system (Zymo) or QIAquick PCR
purification kit (Qiagen). All cDNA generated using the WT-
Ovation
TM One-Direct RNA amplification system was purified
using the MinElute system (Qiagen) as directed by Nugen
Technolgies, Inc. All cDNA probes generated from vascular
endothelial biopsy samples were purified using the QIAquick PCR
purification kit (Qiagen). The vascular endothelial cell biopsy
samples were all processed for cDNA probe generation in batches
including positive controls of 50 ng and 300 pg HUVEC total
RNA and a no template control reaction. Synthesised cDNA
probe concentration was measured by Nanodrop ND-8000
(Nanodrop Technologies, Wilmington, DE, USA). The NuGEN
Technologies FL-Ovation
TM cDNA Biotin Module V2 was used
for cDNA fragmentation and biotin labelling of amplified cDNA
for subsequent hybridisation to the microarrays (Affymetrix, Santa
Clara, CA, USA). The quality of the cDNA probes was assessed
before and after fragmentation with the Agilent 2100 Bioanalyzer
using RNA Nano chips (Agilent Technologies, Santa Clara, CA,
USA).
Affymetrix GeneChips
cDNA probes generated from NuGen Technologies RNA
amplification systems were hybridised to Affymetrix Human
Genome U133 Plus 2.0 Arrays (Affymetrix, Santa Clara, CA,
USA) as described in the Affymetrix Expression Analysis
Technical Manual. Briefly, 5 mg (HUVEC) or 4.5 mg (vascular
endothelial biopsy samples) of fragmented and labelled cDNA,
together with spiked hybridisation controls (GeneChip Expression
39 Amplification Reagents – hybridisation controls), was hybrid-
ised for 18 hrs at 45uC in a rotating oven. Following hybridisation
GeneChip washing and staining was performed using the
GeneChip Hybridisation Wash and Stain kit (Affymetrix, Santa
Clara, CA, USA) on an Affymetrix GeneChip Fluidics Station 450
using the appropriate fluidic script for the U133 Plus 2.0
microarrays with cDNA (FS450-0004). GeneChips were scanned
immediately following staining in an Affymetrix GeneChip
Scanner 3000 (Affymetrix, Santa Clara, USA). MIAME-compliant
array data can be accessed via Gene Expression Omnibus (GEO),
GSE21723.
Data analysis
Report files summarising the quality of target and control
detection for each microarray were generated by GeneChip
Operating Software Version 1.4 (GCOS) using the MAS5.0
algorithm (Affymetrix, Santa Clara, CA, USA). Quality control
analysis was performed using Expression Console (Affymetrix) and
Partek Genomics Suite. Correlation between GeneChips was
assessed by Pearson’s Correlation on the signal from all probes
following MAS5.0 data extraction. Principal component analyses
(PCA) were carried out using Partek Genomics Suite on MAS5.0
normalised data followed by Log2 transformation.
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